Attached files
| file | filename |
|---|---|
| EX-99.1 - PRESS RELEASE - DYNAVAX TECHNOLOGIES CORP | d234560dex991.htm |
| EX-99.2 - DYNAVAX'S ORAL PRESENTATION - DYNAVAX TECHNOLOGIES CORP | d234560dex992.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
Current Report
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 18, 2011
Dynavax Technologies Corporation
(Exact name of registrant as specified in its charter)
Commission File Number: 001-34207
| Delaware | 33-0728374 | |
| (State or other jurisdiction of incorporation) |
(IRS Employer Identification No.) |
2929 Seventh Street, Suite 100
Berkeley, CA 94710-2753
(Address of principal executive offices, including zip code)
(510) 848-5100
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 8.01 | Other Events |
On September 18, 2011, Dynavax Technologies Corporation (Dynavax) issued a press release titled “Dynavax Reports Complete Results from the HEPLISAV™ Phase 3 Trial in Healthy Adults Over Age 40” and presented complete results for the entire study population of its Phase 3 trial (HBV-16) at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Chicago, IL. A copy of the press release and the presentation are attached as Exhibit 99.1 and 99.2, respectively, to this current report and is incorporated herein by reference.
| Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibit
| Exhibit No. | Description | |
| 99.1 | Press Release, dated September 18, 2011, titled “Dynavax Reports Complete Results from the HEPLISAV™ Phase 3 Trial in Healthy Adults Over Age 40” | |
| 99.2 | Dynavax’s Oral Presentation at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| DYNAVAX TECHNOLOGIES CORPORATION | ||||||
| Date: September 21, 2011 |
By: | /s/ Michael S. Ostrach | ||||
| Michael S. Ostrach | ||||||
| Vice President | ||||||
EXHIBIT INDEX
| Exhibit No. | Description | |
| 99.1 | Press Release, dated September 18, 2011, titled “Dynavax Reports Complete Results from the HEPLISAV™ Phase 3 Trial in Healthy Adults Over Age 40” | |
| 99.2 | Dynavax’s Oral Presentation at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) | |